On 22 June 2026, IFPMA delivered a statement at the UN High-Level Meeting on HIV/AIDS in New York.

Excellencies, distinguished delegates, I am pleased to speak on behalf of the IFPMA, representing the innovative pharmaceutical industry.

As Member States gather at this High-Level Meeting to renew global commitments on HIV/AIDS, IFPMA welcomes the Political Declaration’s continued ambition to end AIDS as a public health threat by 2030.

Meaningful progress has been made, but it remains fragile, uneven, and vulnerable to reversal if political attention, funding, and implementation momentum weakens. The priority now is implementation through country-led, evidence-based, and collaboration-oriented access strategies that deliver outcomes for people and communities.

Biomedical innovation has transformed HIV care, enabling people living with HIV and those who could benefit from innovative prevention options to live full, active, and productive lives. We welcome recognition of the important role played by the private sector in innovation, research, and development.

This High-Level Meeting is also an opportunity to sustain ambition for the next generation of HIV innovation, and promote investments in science and technology, including R&D to accelerate progress toward an HIV vaccine and a functional cure for HIV.

Innovation, intellectual property, and equitable access are mutually reinforcing, not competing objectives. The response should prioritize regulatory pathways, supply security, procurement readiness, sustainable financing, and country-led leadership to drive implementation and facilitate access pathways that the private sector enables through collaborations with governments and communities, global and regional institutions, and voluntary licensing.

Finally, as HIV becomes a long-term condition for many, health systems must support long-term health, treatment adherence, and management of co-morbidities across the life course.

IFPMA and its members stand ready to contribute constructively through R&D, manufacturing, partnerships, support for innovation, and practical, evidence-based solutions that strengthen country-led leadership and implementation to sustain long-term progress.

Thank you.

About IFPMA

IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.

To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.

ifpma.org

Media Contact

Elliot Dunster e.dunster@ifpma.org